Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.

Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.